Exforge HCT

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
29-09-2023
Ciri produk Ciri produk (SPC)
29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
20-12-2013

Bahan aktif:

valsartan, hydrochlorothiazide, Amlodipine besilate

Boleh didapati daripada:

Novartis Europharm Limited

Kod ATC:

C09DX01

INN (Nama Antarabangsa):

amlodipine besilate, valsartan, hydrochlorothiazide

Kumpulan terapeutik:

Agents acting on the renin-angiotensin system

Kawasan terapeutik:

Hypertension

Tanda-tanda terapeutik:

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Ringkasan produk:

Revision: 24

Status kebenaran:

Authorised

Tarikh kebenaran:

2009-10-15

Risalah maklumat

                                74
B. PACKAGE LEAFLET
75
PACKAGE LEAFLET: INFORMATION FOR THE USER
EXFORGE HCT 5 MG/160 MG/12.5 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/160 MG/12.5 MG FILM-COATED TABLETS
EXFORGE HCT 5 MG/160 MG/25 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/160 MG/25 MG FILM-COATED TABLETS
EXFORGE HCT 10 MG/320 MG/25 MG FILM-COATED TABLETS
amlodipine/valsartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Exforge HCT is and what it is used for
2.
What you need to know before you take Exforge HCT
3.
How to take Exforge HCT
4.
Possible side effects
5.
How to store Exforge HCT
6.
Contents of the pack and other information
1.
WHAT EXFORGE HCT IS AND WHAT IT IS USED FOR
Exforge HCT tablets contain three substances called amlodipine,
valsartan and hydrochlorothiazide.
All of these substances help to control high blood pressure.
−
Amlodipine belongs to a group of substances called “calcium channel
blockers”. Amlodipine
stops calcium from moving into the blood vessel wall, which stops the
blood vessels from
tightening.
−
Valsartan belongs to a group of substances called “angiotensin-II
receptor antagonists”.
Angiotensin II is produced by the body and makes the blood vessels
tighten, thus increasing the
blood pressure. Valsartan works by blocking the effect of angiotensin
II.
−
Hydrochlorothiazide belongs to a group of substances called
“thiazide diuretics”.
Hydrochlorothiazide increases urine output, which also lowers blood
pressure.
As a result of all three mechanisms, the blood v
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 12.5 mg of hydrochlorothiazide.
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 12.5 mg of hydrochlorothiazide.
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 25 mg of hydrochlorothiazide.
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 160 mg of valsartan,
and 25 mg of hydrochlorothiazide.
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate), 320 mg of valsartan
and 25 mg of hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
White, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VCL” on the
other side. Approximate size: 15 mm (length) x 5.9 mm (width).
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Pale yellow, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VDL”
on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Yellow, ovaloid, biconvex tablets with bevelled edge, debossed
“NVR” on one side and “VEL” on the
other side. Approximate size: 15 mm
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 29-09-2023
Ciri produk Ciri produk Bulgaria 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 12-12-2013
Risalah maklumat Risalah maklumat Sepanyol 29-09-2023
Ciri produk Ciri produk Sepanyol 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 12-12-2013
Risalah maklumat Risalah maklumat Czech 29-09-2023
Ciri produk Ciri produk Czech 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 12-12-2013
Risalah maklumat Risalah maklumat Denmark 29-09-2023
Ciri produk Ciri produk Denmark 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 12-12-2013
Risalah maklumat Risalah maklumat Jerman 29-09-2023
Ciri produk Ciri produk Jerman 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 12-12-2013
Risalah maklumat Risalah maklumat Estonia 29-09-2023
Ciri produk Ciri produk Estonia 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 12-12-2013
Risalah maklumat Risalah maklumat Greek 29-09-2023
Ciri produk Ciri produk Greek 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 12-12-2013
Risalah maklumat Risalah maklumat Perancis 29-09-2023
Ciri produk Ciri produk Perancis 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 12-12-2013
Risalah maklumat Risalah maklumat Itali 29-09-2023
Ciri produk Ciri produk Itali 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 12-12-2013
Risalah maklumat Risalah maklumat Latvia 29-09-2023
Ciri produk Ciri produk Latvia 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 12-12-2013
Risalah maklumat Risalah maklumat Lithuania 29-09-2023
Ciri produk Ciri produk Lithuania 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 12-12-2013
Risalah maklumat Risalah maklumat Hungary 29-09-2023
Ciri produk Ciri produk Hungary 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 12-12-2013
Risalah maklumat Risalah maklumat Malta 29-09-2023
Ciri produk Ciri produk Malta 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 12-12-2013
Risalah maklumat Risalah maklumat Belanda 29-09-2023
Ciri produk Ciri produk Belanda 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 12-12-2013
Risalah maklumat Risalah maklumat Poland 29-09-2023
Ciri produk Ciri produk Poland 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 12-12-2013
Risalah maklumat Risalah maklumat Portugis 29-09-2023
Ciri produk Ciri produk Portugis 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 12-12-2013
Risalah maklumat Risalah maklumat Romania 29-09-2023
Ciri produk Ciri produk Romania 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 12-12-2013
Risalah maklumat Risalah maklumat Slovak 29-09-2023
Ciri produk Ciri produk Slovak 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 12-12-2013
Risalah maklumat Risalah maklumat Slovenia 29-09-2023
Ciri produk Ciri produk Slovenia 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 12-12-2013
Risalah maklumat Risalah maklumat Finland 29-09-2023
Ciri produk Ciri produk Finland 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 12-12-2013
Risalah maklumat Risalah maklumat Sweden 29-09-2023
Ciri produk Ciri produk Sweden 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 12-12-2013
Risalah maklumat Risalah maklumat Norway 29-09-2023
Ciri produk Ciri produk Norway 29-09-2023
Risalah maklumat Risalah maklumat Iceland 29-09-2023
Ciri produk Ciri produk Iceland 29-09-2023
Risalah maklumat Risalah maklumat Croat 29-09-2023
Ciri produk Ciri produk Croat 29-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 12-12-2013

Lihat sejarah dokumen